Antylia Scientific Acquisitions
See Antylia Scientific funding rounds, investors, investments, exits and more. Evaluate their financials based on Antylia Scientific's post-money valuation and revenue.
www.cbinsights.comHere’s a concise briefing on the latest publicly reported news about Antylia Scientific.
-
The most notable recent development: private equity firm GTCR completed the sale of Antylia Scientific to Brookfield Asset Management's private equity division and CDPQ for about $1.34 billion. This marks a significant ownership change after a period of strategic transformation and growth efforts at Antylia. The announcement emphasizes Antylia’s path from its Cole-Parmer lineage into a broader life sciences tools platform, with two operating divisions and ongoing emphasis on organic investment and acquisitions.[1][3]
-
Context on past corporate moves: Antylia Scientific originated from Cole-Parmer Instrument Company and rebranded to reflect a broader focus on life sciences, bioprocessing, and related diagnostics products; the company has historically pursued a strategy of expanding through both internal development and acquisitions.[3][4]
-
Related market context: Antylia has notable connections to its former Masterflex bioprocessing business segment, which was divested to Avantor in late 2021, a move aligned with transforming the business toward higher-growth bioprocessing assets and supportive diagnostics lines.[1]
If you’d like, I can pull a current copy of the Brookfield/CDPQ press release for precise quotes and add a brief timeline of Antylia’s major corporate milestones.